Drug Reimbursement Recommendation - Idhifa and Vitrakvi

Today, CADTH has issued final recommendations for:

Enasidenib (Idhifa) for Acute Myeloid Leukemia

Funding Request: For the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation
Recommendation: Do not reimburse
Notification to implement target date: November 15, 2019

For more information

Larotrectinib (Vitrakvi) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours

Funding Request: For the treatment of adult and pediatric patients with locally advanced or metastatic solid tumours harbouring a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. Additional criteria: Age ≥ 1 month; ECOG score of ≤3; Tumour harbouring NTRK1, NTRK2 or NTRK3 gene fusion confirmed by a validated diagnostic testing method; Patients eligible for larotrectinib should have no satisfactory alternative treatments or have progressed following treatment
Recommendation: Do not reimburse
Notification to implement target date: November 15, 2019

For more information